Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent nucleos (t) ide analogues
(NUCs) recommended as first‐line monotherapies for chronic hepatitis B. In Phase III trials …

Results from phase III clinical trials clearly demonstrate the efficacy and safety of entecavir
and tenofovir in the controlled environment of randomized clinical studies. There are several …

Aim Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are considered among the most
potent antiviral agents for the treatment of chronic hepatitis B infection. We aimed to …

Background There have been limited studies directly comparing the long-term efficacy
between entecavir (ETV) and tenofovir disoproxil fumarate (TDF). This study was aimed to …

The efficacy of entecavir and tenofovir in patients with chronic hepatitis B virus (HBV) is
inconsistent. To address this issue, we conducted a meta‐analysis based on a current …

BACKGROUND & AIMS: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent
antiviral agents that might have additive or synergistic antiviral activity in treatment of …

Introduction Both entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are first-line
therapies for chronic hepatitis B (CHB), but their comparative effectiveness with regards to …

Aim The study aimed to evaluate the efficacy and safety of tenofovir disoproxil fumarate
(TDF) and entecavir hydrate (ETV) in nucleos (t) ide analog (NA)‐naïve Japanese chronic …

Abstract Background and Aims Tenofovir disoproxil fumarate (TDF) demonstrated potent
and sustainable antiviral efficacy and a good safety profile in patients with chronic hepatitis …

Background Tenofovir alafenamide (TAF) may be preferable to other nucleos (t) ide
analogues (NA) regarding outcomes against chronic hepatitis B virus (HBV) infection. Aims …